Immunome (NASDAQ:IMNM) Now Covered by Lake Street Capital

Lake Street Capital initiated coverage on shares of Immunome (NASDAQ:IMNM) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $23.00 price target on the stock.

IMNM has been the topic of several other research reports. Lifesci Capital began coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Stephens reissued an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Finally, Guggenheim dropped their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $25.14.

Immunome Price Performance

Shares of IMNM opened at $5.93 on Wednesday. The firm has a 50-day simple moving average of $9.13 and a two-hundred day simple moving average of $11.03. The stock has a market cap of $515.62 million, a PE ratio of -0.73 and a beta of 2.05. Immunome has a 1-year low of $5.75 and a 1-year high of $21.72.

Immunome (NASDAQ:IMNM) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. As a group, sell-side analysts expect that Immunome will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $8.42 per share, with a total value of $103,566.00. Following the transaction, the chief technology officer now directly owns 33,300 shares in the company, valued at approximately $280,386. The trade was a 58.57 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. Wellington Management Group LLP lifted its position in Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Immunome by 5.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock valued at $441,000 after purchasing an additional 2,005 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Immunome by 32.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,193 shares of the company’s stock worth $618,000 after purchasing an additional 14,328 shares in the last quarter. Woodline Partners LP grew its stake in Immunome by 6.1% in the 4th quarter. Woodline Partners LP now owns 980,925 shares of the company’s stock worth $10,417,000 after acquiring an additional 56,533 shares during the period. Finally, Two Sigma Advisers LP purchased a new position in shares of Immunome during the 4th quarter worth about $512,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.